相关实验视频

Updated: Jul 4, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

一种针对线粒体的抗癌铜二甲基酸盐增强了免疫性cuproptosis和巨细胞两极分化

Yao Lu¹, Xi Fan¹, Qingqing Pan²

¹National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, China. bhe@scu.edu.cn.

Journal of materials chemistry. B

|January 31, 2024

概括

研究人员开发了一种新的铜复合物TPP-CuET,该复合物向线粒体,诱导乳腺癌细胞中的免疫性杯亡. 这种方法通过重塑巨细胞和激活免疫细胞来增强抗瘤免疫力.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
癌症生物学癌症生物学

背景情况:

铜,一种由铜复合物 (如铜二二甲基甲酸盐) (CuET) 诱导的细胞死亡形式,是癌症治疗中的新治疗标.
准线粒体代谢提供了一种潜在的策略,可以增强癌细胞死亡并触发抗瘤免疫反应.

研究的目的:

设计和评估一种用三基改性CuET (TPP-CuET),用于向线粒体输送和诱导乳腺癌中的免疫性cuproptosis.
研究TPP-CuET对线粒体功能,癌细胞死亡,巨细胞两极分化和抗瘤免疫细胞激活的影响.

主要方法:

合成三基改性铜 (II) 双 (二甲基二甲基酸盐) (TPP-CuET).
评估线粒体铜积累,线粒体形态和功能 (TCA循环,ATP合成,ETC).
通过转录组分析和MHC I通路,分析癌细胞死亡,巨细胞偏振 (M1) 和免疫细胞激活 (CD8 T细胞,NK细胞).

主要成果:

与CuET相比,TPP-CuET显著增强了线粒体中的铜积累 (29.0%与19.4%相比).
TPP-CuET 破坏了线粒体形态和功能,导致强化的免疫性癌细胞死亡和损伤相关分子模式的释放.
TPP-CuET促进了M1巨细胞的极化和迁移,通过MHC I增强了抗原的处理和呈现,并激活了CD8 T细胞和自然杀手细胞.

结论:

TPP-CuET是第一个被发现的免疫性cuproptosis的线粒体向诱导剂.
这种新型药物有效地重塑瘤微环境,增强抗瘤免疫力.
作为抗瘤免疫治疗的治疗策略,TPP-CuET具有显著的前景.

更多相关视频

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.